In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …

The hallmarks of COVID-19 are higher pathogenicity and mortality in the elderly compared
to children. Examining baseline SARS-CoV-2 cross-reactive immunological responses …

The rapid scale-up of research on coronavirus disease 2019 (COVID-19) has spawned a
large number of potential vaccines and immunotherapies, accompanied by a …

Combination antiretroviral therapy (cART) is effective but not curative, and no successful
vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly …

Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are
promising molecules for therapeutic or prophylactic interventions. Beyond neutralization …

A considerable body of evidence suggests that Fc-dependent functions improve the capacity
of broadly neutralizing antibodies (BnAbs) to protect against and control HIV-1 infection. This …

Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains
an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional …

HIV-1 spreads through contacts between infected and target cells. Polarized viral budding at
the contact site forms the virological synapse. Additional cellular processes, such as …

Passive immunization using broadly neutralizing antibodies (bNAbs) is investigated in
clinical settings to inhibit HIV-1 acquisition due to the lack of a preventive vaccine. However …